Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 22 March 2021, 09:38 HKT/SGT
Share:
    

Source: Eisai
Eisai Awarded The New Diversity Management Selection 100

TOKYO, Mar 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program.

METI has been presenting a METI Minister's Award under the New Diversity Management Selection 100 Program since its inauguration in FY 2012 with the aim of widely introducing the advanced efforts of companies that link diversity promotion to management results and encouraging companies to engage in diversity management. In the FY2020 award, among the priority themes of the New Diversity Management Selection 100 Program, Eisai received a particularly high evaluation for items such as activities promoting participation of diverse employees including women and employees with foreign nationalities, realizing diverse career paths for employees, and implementing workstyle innovation and management strategy transformation, and so on.

Eisai defines its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. Eisai believes that, in order to realize the hhc philosophy, it is important for each Eisai employee to firstly get close to patients, see the situation from their perspectives in order to learn to empathize with thoughts and feelings that might not necessarily always be expressed in words. The hhc philosophy pervades the awareness of each and every employee of the Eisai Group and is put into practice in our daily work. Eisai is working on the Diversity & Inclusion as a management strategy to sustainably realize the hhc philosophy no matter how the social environment changes. Eisai has been promoting its initiatives to support the active participation of diverse employees such as women and employees with foreign nationalities, by improving environments surrounding employees, reforming workstyles, and changing the mindset of all employees. In addition, Eisai is enhancing to develop human resources across Eisai Group worldwide, such as the programs designed for developing global leaders that Eisai has continuously promoted for many years.

Eisai continues to promote the Diversity & Inclusion Strategy in order to response to the diversifying needs of patients, their families, and consumers and to realize the hhc philosophy.

* For more information on Eisai's Strategy for Talents Innovation, including its initiatives toward diversity at Eisai, please see Eisai Integrated Report. https://www.eisai.com/ir/library/annual/index.html


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: